Description: <b>Vitamin</b> like substance. Found in cereals, nuts and legumes.<br>
Inositol hexaphosphate (IP6) is a dietary component that constitutes approximately 1 to 5% of the weight of most cereals, nuts, oil seeds, legumes, and grains [1, 2]. In particular, approximately 9.5 to 14.5% of the weight of rice bran is composed of IP6. <br>
<br>
<p><b>IP6 (inositol hexaphosphate)</b> — also called myo-inositol hexakisphosphate, InsP6, phytic acid, or phytate, is a naturally occurring highly phosphorylated inositol carbohydrate abundant in cereal grains, legumes, nuts, seeds, and rice bran and also present at lower concentrations in mammalian cells. It is formally classified as a dietary phytochemical / polyphosphorylated inositol and is marketed as a dietary supplement rather than an approved anticancer drug. Standard abbreviations include IP6 and InsP6. Its unusually high negative charge gives it strong multivalent-cation binding properties, particularly toward iron, zinc, calcium, and magnesium. Experimental anticancer effects are broad but predominantly preclinical, and the extracellular millimolar concentrations commonly used in cancer-cell experiments are far above measured circulating human concentrations.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Suppression of PI3K/PDK1/AKT/mTOR survival and growth signaling, including reduced AKT and p70S6K phosphorylation.</li>
<li>Cell-cycle inhibition through ↑ p21 and p27, ↓ cyclin D1/CDK activity, ↓ pRB phosphorylation, and reduced E2F signaling, producing predominantly G1 arrest.</li>
<li>Induction of apoptosis through inhibition of prosurvival AKT signaling, ↑ Bax/Bcl-2 ratio, caspase activation, and PARP cleavage.</li>
<li>Suppression of NF-κB and related inflammatory/prosurvival signaling, including inhibition of IKK/IκB signaling in responsive cancer models.</li>
<li>Anti-invasive and antimetastatic activity through ↓ integrin/focal-adhesion signaling, ↓ MMP expression or secretion, reduced migration and invasion, and in some models suppression of EMT.</li>
<li>Antiangiogenic activity associated with ↓ VEGF, HIF-1α, eNOS, and tumor microvascular markers in preclinical models.</li>
<li>Modulation of MAPK, PKC, RAS/ERK, AP-1, and related growth-regulatory signal-transduction networks in a model-dependent manner.</li>
<li>Promotion of cancer-cell differentiation toward a less malignant phenotype, reported across several experimental tumor systems.</li>
<li>Iron and transition-metal chelation with inhibition of metal-catalyzed hydroxyl-radical generation; this antioxidant mechanism is biologically relevant but is not equivalent to the intracellular cytotoxic mechanisms observed at high experimental IP6 concentrations.</li>
<li>Immune Modulation: – Some studies suggest that IP6 may enhance the immune response against tumors, contributing to its overall anti-cancer activity.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral IP6 is measurably absorbed in humans but systemic exposure is very low. Human studies report basal plasma concentrations around 0.07 mg/L during an IP6-poor diet and approximately 0.26 mg/L during a normal IP6-containing diet, with a plasma maximum occurring roughly 4 hours after an oral dose. IP6 is highly charged, undergoes gastrointestinal interactions with minerals, and can be dephosphorylated to lower inositol phosphates after uptake. Oral exposure therefore does not reproduce the extracellular millimolar concentrations commonly used in cell culture.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is a major translational limitation. Many anticancer experiments use approximately 0.5–5 mM IP6, equivalent to roughly 330–3300 mg/L, whereas measured human plasma IP6 is typically well below 1 mg/L. Thus common in-vitro concentrations exceed measured circulating exposure by roughly three to four orders of magnitude. At millimolar concentrations IP6 also strongly chelates cations and can alter culture-medium chemistry, so some reported effects require cautious interpretation. Tissue uptake, local gastrointestinal exposure, and formation of lower inositol phosphates may nevertheless produce biological effects not predicted solely from plasma IP6 concentration.</p>
<p><b>Clinical evidence status:</b> <b>Small human / adjunct use; not established anticancer therapy.</b> The strongest cancer evidence remains cell-culture and animal work. Small randomized or prospective breast-cancer studies of IP6 with myo-inositol and/or topical IP6 during chemotherapy have reported better quality-of-life measures and attenuation of some treatment-associated hematologic or local symptoms, but these trials were small and were not adequate demonstrations of improved tumor response, progression-free survival, or overall survival. IP6 has no established regulatory approval for cancer treatment. A separate long-term oral IP6 study in superficial siderosis is registered but remains listed as not yet recruiting and does not establish efficacy. The principal practical safety constraint is mineral chelation: high phytate exposure can reduce iron and zinc absorption, particularly when nutritional status is marginal. Caution is also appropriate with significant iron deficiency and with anticoagulant therapy because antiplatelet effects have been reported.</p>
<h3>IP6 Cancer-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PI3K AKT mTOR survival signaling</td>
<td>↓ PI3K, PDK1, AKT phosphorylation, mTOR signaling, p70S6K</td>
<td>↔ / context-dependent</td>
<td>↓ proliferation and survival; ↑ apoptosis</td>
<td>One of the best-supported anticancer axes. Demonstrated in prostate and colon cancer models. In-vitro effects commonly require millimolar IP6.</td>
</tr>
<tr>
<td>2</td>
<td>Cell-cycle control</td>
<td>↑ p21; ↑ p27; ↓ cyclin D1; ↓ CDK2/CDK4 activity; ↓ pRB phosphorylation; ↓ E2F</td>
<td>↔ / context-dependent</td>
<td>↑ G1 cell-cycle arrest</td>
<td>Strong mechanistic evidence in prostate and other cancer-cell models. Direction of individual regulators can vary by cell type and experimental conditions.</td>
</tr>
<tr>
<td>3</td>
<td>Apoptotic machinery</td>
<td>↑ Bax/Bcl-2 ratio; ↑ caspase-3; ↑ caspase-9; ↑ PARP cleavage</td>
<td>Generally much less cytotoxic</td>
<td>↑ programmed cancer-cell death</td>
<td>Closely coupled to suppression of AKT and other survival signaling.</td>
</tr>
<tr>
<td>4</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓ IKK activity; ↓ IκB phosphorylation; ↓ nuclear NF-κB p50/p65</td>
<td>↓ inflammatory signaling (context-dependent)</td>
<td>↓ prosurvival and inflammatory transcription</td>
<td>Demonstrated particularly in constitutively active prostate-cancer models and stress-induced signaling systems.</td>
</tr>
<tr>
<td>5</td>
<td>Migration invasion and extracellular matrix</td>
<td>↓ adhesion; ↓ migration; ↓ invasion; ↓ MMP-2/MMP-3/MMP-9 and related MMP signaling</td>
<td>Not well established</td>
<td>↓ metastatic phenotype</td>
<td>Breast and colon cancer studies show reduced extracellular-matrix adhesion, motility, invasion, and MMP activity or expression.</td>
</tr>
<tr>
<td>6</td>
<td>Integrin and focal-adhesion signaling</td>
<td>↓ α2β1; ↓ α5β1; ↓ αvβ3-related adhesion signaling (model-dependent)</td>
<td>Not established</td>
<td>↓ attachment and motility</td>
<td>Supports the anti-invasive phenotype but evidence is predominantly older in-vitro work.</td>
</tr>
<tr>
<td>7</td>
<td>EMT and epithelial differentiation</td>
<td>↓ EMT; ↑ E-cadherin; ↓ N-cadherin; ↑ claudin-7 in selected IP6 plus inositol models</td>
<td>↔ / not established</td>
<td>↓ metastatic plasticity; ↑ epithelial phenotype</td>
<td>Recent colorectal models support EMT suppression, particularly with IP6 plus myo-inositol. Combination findings should not automatically be attributed to IP6 alone.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis and hypoxic signaling</td>
<td>↓ VEGF; ↓ HIF-1α; ↓ eNOS; ↓ CD31</td>
<td>Not well established</td>
<td>↓ tumor angiogenesis</td>
<td>Supported mainly by prostate xenograft and related preclinical models.</td>
</tr>
<tr>
<td>9</td>
<td>RAS MAPK PKC AP-1 signaling</td>
<td>↓ growth-promoting signaling (model-dependent)</td>
<td>Context-dependent</td>
<td>↓ proliferation and tumor-promoting transcription</td>
<td>IP6 affects several interconnected signaling pathways; individual MAPK components do not show a uniform direction across all experimental systems.</td>
</tr>
<tr>
<td>10</td>
<td>Wnt β-catenin signaling</td>
<td>↓ Wnt/β-catenin activity (model-dependent)</td>
<td>Not established</td>
<td>↓ proliferation and metastatic progression</td>
<td>Supported mainly by colorectal cancer animal studies, including IP6 plus inositol combinations.</td>
</tr>
<tr>
<td>11</td>
<td>Cancer-cell differentiation</td>
<td>↑ differentiation; ↓ malignant phenotype</td>
<td>↔</td>
<td>Phenotypic normalization</td>
<td>Repeatedly reported experimentally, although the precise responsible signaling pathway varies among tumor systems.</td>
</tr>
<tr>
<td>12</td>
<td>Transition-metal chelation and oxidative stress</td>
<td>↓ Fe-mediated hydroxyl-radical generation; ROS response variable</td>
<td>↓ oxidative damage</td>
<td>Antioxidant and metal-binding activity</td>
<td>IP6 strongly complexes iron and other polyvalent cations. ROS should not be assigned a universal ↑ or ↓ direction in cancer cells because redox effects depend heavily on model, dose, metal availability, and extracellular chemistry.</td>
</tr>
<tr>
<td>13</td>
<td>Chemosensitization and treatment tolerance</td>
<td>↑ treatment response in some preclinical models</td>
<td>↓ selected chemotherapy-associated toxicity in small human studies</td>
<td>Potential adjunctive effect</td>
<td>Human evidence is more convincing for supportive-care outcomes than for enhanced tumor control. Combination with myo-inositol is common in clinical reports.</td>
</tr>
<tr>
<td>14</td>
<td>Clinical Translation Constraint</td>
<td>Experimental activity often requires 0.5–5 mM extracellular IP6</td>
<td>High intake can ↓ iron and zinc bioavailability</td>
<td>Limits direct translation of cell-culture anticancer effects</td>
<td>Measured human plasma exposure is far below common anticancer cell-culture concentrations. High concentrations can chelate culture-medium metals and alter experimental conditions. Cancer trials are small and have not established tumor-control or survival benefit.</td>
</tr>
</tbody>
</table>